Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression

Table 2 Univariate and multivariate analysis with respect to progression free survival in 177 all breast cancers

Parameters	Univariate analysis			Multivariate analysis
Parameters	Hazard ratio	95% CI	p value	Hazard ratio	95% CI	p value
Subtype TNBC vs non-TNBC	1.213	0.577–2.550	0.611	0.849	0.387–1.861	0.683
Subtype HER2⁺BC vs non-HER2⁺BC	0.421	0.147–1.206	0.107	0.552	0.181–1.686	0.297
Lymph node status Positive vs negative	4.157	0.990–17.456	0.052	4.330	1.027–18.263	0.046
Pathological response pCR vs Non-pCR	0.611	0.279–1.336	0.217	0.854	0.352–2.072	0.728
PD-1 Positive vs negative	2.752	1.300–5.826	0.008	1.415	0.526–3.811	0.492
PD-L1 Positive vs negative	3.194	1.544–6.607	0.002	2.613	0.879–7.766	0.084

CI confidence interval, TNBC triple-negative breast cancer, HER2 human epidermal growth factor receptor 2, BC breast cancer, pCR pathological complete response, PD-1 programmed cell death-1, PD-L programmed cell death-ligand

ISSN: 1479-5876